These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 30890701)

  • 1. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
    Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
    Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RSUME inhibits VHL and regulates its tumor suppressor function.
    Gerez J; Tedesco L; Bonfiglio JJ; Fuertes M; Barontini M; Silberstein S; Wu Y; Renner U; Páez-Pereda M; Holsboer F; Stalla GK; Arzt E
    Oncogene; 2015 Sep; 34(37):4855-66. PubMed ID: 25500545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism.
    Martinefski MR; Elguero B; Knott ME; Gonilski D; Tedesco L; Gurevich Messina JM; Pollak C; Arzt E; Monge ME
    J Proteome Res; 2021 Jan; 20(1):786-803. PubMed ID: 33124415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
    Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
    Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
    Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
    Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.
    Lai Y; Song M; Hakala K; Weintraub ST; Shiio Y
    Arch Biochem Biophys; 2012 Feb; 518(2):103-10. PubMed ID: 22234250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
    Raval RR; Lau KW; Tran MG; Sowter HM; Mandriota SJ; Li JL; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Mol Cell Biol; 2005 Jul; 25(13):5675-86. PubMed ID: 15964822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
    Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
    Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
    Andreou A; Yngvadottir B; Bassaganyas L; Clark G; Martin E; Whitworth J; Cornish AJ; ; Houlston RS; Rich P; Egan C; Hodgson SV; Warren AY; Snape K; Maher ER
    Hum Mol Genet; 2022 Aug; 31(16):2728-2737. PubMed ID: 35323939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.